2269:HKG
WuXi Biologics (Cayman) Inc
HK$Â 48.20
arrow_downward
-0.90%(-0.44) Siku 1
16 Okt, 16:08:14 GMT +8 · HKD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya 2269...
Fungua
HK$Â 49.98
Juu
HK$Â 50.85
Chini
HK$Â 45.82
Mtaji wa soko
198.43B
Wastani wa kiasi cha mauzo
30.42M
Kiasi cha mauzo ya hisa
55.18M
Uwiano wa bei ya hisa na mapato kwa kila hisa
34.48
Juu kwa wiki 52
HK$Â 58.00
Chini kwa wiki 52
HK$Â 28.48
EPS
HK$Â 1.40
Hisa za wawekezaji
1.23B
Idadi ya wafanyakazi
elfu 15
Fungua
HK$Â 49.98
Juu
HK$Â 50.85
Chini
HK$Â 45.82
Mtaji wa soko
198.43B
Wastani wa kiasi cha mauzo
30.42M
Kiasi cha mauzo ya hisa
55.18M
Uwiano wa bei ya hisa na mapato kwa kila hisa
34.48
Juu kwa wiki 52
HK$Â 58.00
Chini kwa wiki 52
HK$Â 28.48
EPS
HK$Â 1.40
Hisa za wawekezaji
1.23B
Idadi ya wafanyakazi
elfu 15
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Stock Traders Daily
·
saa 4 zilizopita
Behavioral Patterns of JMKE and Institutional Flows
Benzinga
·
dakika 30 zilizopita
Dow Jones, Nasdaq 100, S&P 500 Outlook: Top Catalysts to Move US Stocks This Week
Simply Wall Street
·
dakika 39 zilizopita
Did FDA Filings Just Shift Cogent Biosciences Stock Investment Narrative?
Wasifu
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Kuhusu WuXi Biologics (Cayman) Inc
Afisa Mkuu Mtendaji (CEO)Zhisheng Chen
Wafanyakazielfu 14.7
Lilianzishwa2010
Makao makuu-
Sekta-
Tovutiwuxibiologics.com